The findings reach people, from one lab or study. 14 independent labs in 8 countries.
“FABP4 yielded the largest positive mediated proportions (AF, 49.8%; HF, 32.9%) and transition-specific signals for baseline-to-AF and AF-to-comorbidity.”
Cells, mice and humans: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Includes the processes named after it and trials of drugs aimed at it.
14 independent labs in 8 countries
Funders: National Institutes of Health and others
Human trial4
Humans19
Animals35
Cells11
Interventions
3
High-fat diet
↑upin mice1
1 study
High-fat diet increases FABP4 in mice during aging.
“bone marrow macrophages of the LHA group upregulated Chil3 and Fabp4”
Elamipretide decreases FABP4 in degenerative tenocytes.
“fatty acid-binding protein 4 (fatty infiltration, P = .046) was significantly upregulated in the degenerative tenocytes and reduced by SS-31 treatment (P = .048; P = .007)”
Docosahexaenoic acid decreases FABP4 in human Mesenchymal Stromal Cells during treatment with rosiglitazone.
“confirming the beneficial effect of docosahexaenoic acid (DHA) omega-3 FA during treatment with rosiglitazone, through the down-regulation of adipogenic genes”
Cellsin human Mesenchymal Stromal Cells during treatment with rosiglitazone
FABP4 is linked with atrial fibrillation in humans (positive mediated proportions) (49.8% mediated proportion for AF, 32.9% for HF).
“FABP4 yielded the largest positive mediated proportions (AF, 49.8%; HF, 32.9%) and transition-specific signals for baseline-to-AF and AF-to-comorbidity.”
FABP4 increases inflammation in mice (shown by Fabp4/5 deficiency).
“Fabp-deficient mice exhibit extended metabolic healthspan, with protection against insulin resistance and glucose intolerance, inflammation, deterioration of adipose tissue integrity, and fatty liver disease.”
FABP4 raises the risk of fatty liver disease in mice (shown by Fabp4/5 deficiency).
“Fabp-deficient mice exhibit extended metabolic healthspan, with protection against insulin resistance and glucose intolerance, inflammation, deterioration of adipose tissue integrity, and fatty liver disease.”
FABP4 raises the risk of insulin resistance in mice (shown by Fabp4/5 deficiency).
“Fabp-deficient mice exhibit extended metabolic healthspan, with protection against insulin resistance and glucose intolerance, inflammation, deterioration of adipose tissue integrity, and fatty liver disease.”
FABP4 predicts cardio-ankle vascular index in kidney transplant patients (p = 0.003).
“Multivariate forward stepwise linear regression analysis showed that age (p = 0.004), systolic blood pressure (p = 0.001), and serum A-FABP levels (p = 0.003) were independent predictors of CAVI value in KT patients.”
People with poor heart and metabolic health and pre-frailty or frailty had a heart failure hazard ratio of 2.76 versus healthy, non-frail participants.People with poor heart and metabolic health and pre-frailty or frailty had a heart failure hazard ratio of 2.76 versus healthy, non-frail participants.
People with intramuscular fat fractions above 10% showed significantly lower paraspinal muscle mass and strength than those with levels below 5%.People with intramuscular fat fractions above 10% showed significantly lower paraspinal muscle mass and strength than those with levels below 5%.